Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors Has extensive experience in pharma and biotech in U.S., Europe and globally Galecto completed U.S. initial public offering and plans t

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements

include statements about Galecto s clinical trial plans, the significance and participation of a new board member, Galecto s growth, and Galecto s products and pipeline. The words may, will, could,

would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential,

continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of

the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and

uncertainties related to the development of Galecto s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto s filings with the Securities and Exchange Commission, including

its Registration Statement on Form S-1. These forward-looking statements represent Galecto s judgment as of the time of this release. Galecto disclaims any intent or obligation to update these

forward-looking statements, other than as may be required under applicable law.

For more information, contact: